Clinical Trials

600 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06623422 2026-03-11

INTerpath-009

680 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06890598 2026-03-03

SUNRAY-02

700 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06868277 2026-03-02

ARTEMIDELung04

830 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05920356 2026-02-27

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

750 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03774732 2026-02-25

NIRVANA-LUNG

327 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06692738 2026-02-25

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

880 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07431827 2026-02-25

KANDLELIT-013

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06767514 2026-02-24

HARMONi-7

780 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04738487 2026-02-20

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Phase 3 Completed

1,264 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05555732 2026-02-19

TROPION-Lung07

1,170 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07361510 2026-02-19

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

750 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06698042 2026-02-09

MK-3475A-F84

67 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05226598 2026-02-05

MK-7684A-007

Phase 3 Completed

739 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05502237 2026-01-30

STAR-121

1,021 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07222566 2026-01-23

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

1,410 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT07362459 2026-01-23

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

246 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06899126 2026-01-08

DESTINY-Lung06

686 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05215340 2026-01-07

TROPION-Lung08

740 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05899608 2026-01-07

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

1,600 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05048797 2025-12-23

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

454 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06216301 2025-12-17

LUNAR-2

734 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06908993 2025-12-17

COMET

133 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03924869 2025-12-11

KEYNOTE-867

Phase 3 Terminated

448 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05317858 2025-12-10

LIMITLESS

30 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06280196 2025-12-02

A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC

Phase 3 Terminated

162 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06348199 2025-11-17

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

555 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06212752 2025-11-12

MK-3475A-D77

39 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT06008093 2025-10-27

TRITON

280 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04194944 2025-10-21

LIBRETTO-431

261 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT03520686 2025-10-16

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

1,538 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04547504 2025-09-17

PERSEE

349 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05722015 2025-09-11

MK-3475A-D77

377 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06472076 2025-09-10

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

88 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07162883 2025-09-09

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

122 enrolled

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Lymphatic Metastasis, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05298423 2025-08-01

KEYVIBE-006

611 enrolled